CN101932594A - 可用作疫苗的自装配肽纳米颗粒 - Google Patents

可用作疫苗的自装配肽纳米颗粒 Download PDF

Info

Publication number
CN101932594A
CN101932594A CN2009801037674A CN200980103767A CN101932594A CN 101932594 A CN101932594 A CN 101932594A CN 2009801037674 A CN2009801037674 A CN 2009801037674A CN 200980103767 A CN200980103767 A CN 200980103767A CN 101932594 A CN101932594 A CN 101932594A
Authority
CN
China
Prior art keywords
peptide
cell epitope
coiled
composition
coil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801037674A
Other languages
English (en)
Chinese (zh)
Inventor
P·布克哈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha O Peptides AG
Original Assignee
Alpha O Peptides AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39276265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101932594(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alpha O Peptides AG filed Critical Alpha O Peptides AG
Publication of CN101932594A publication Critical patent/CN101932594A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN2009801037674A 2008-02-01 2009-01-29 可用作疫苗的自装配肽纳米颗粒 Pending CN101932594A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08101221 2008-02-01
EP08101221.3 2008-02-01
PCT/EP2009/050996 WO2009109428A2 (en) 2008-02-01 2009-01-29 Self-assembling peptide nanoparticles useful as vaccines

Publications (1)

Publication Number Publication Date
CN101932594A true CN101932594A (zh) 2010-12-29

Family

ID=39276265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801037674A Pending CN101932594A (zh) 2008-02-01 2009-01-29 可用作疫苗的自装配肽纳米颗粒

Country Status (8)

Country Link
US (1) US8546337B2 (https=)
EP (1) EP2235043A2 (https=)
JP (1) JP6088123B2 (https=)
CN (1) CN101932594A (https=)
AU (1) AU2009221419B2 (https=)
CA (1) CA2713879C (https=)
RU (1) RU2540871C2 (https=)
WO (1) WO2009109428A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011065A (zh) * 2011-08-23 2014-08-27 哈佛大学校长及研究员协会 肽纳米粒子及其用途
CN104136454A (zh) * 2011-10-12 2014-11-05 阿尔法-O肽股份公司 作为针对诺如病毒感染的疫苗的自装配肽纳米粒
CN105960412A (zh) * 2014-01-09 2016-09-21 阿尔法欧多肽股份公司 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒
CN110290805A (zh) * 2017-01-03 2019-09-27 埃默杰克斯疫苗控股有限公司 通用流感疫苗组合物
CN110996995A (zh) * 2017-03-23 2020-04-10 阿尔法-O肽股份公司 具有内置六螺旋束蛋白的自组装蛋白纳米粒子
CN111150841A (zh) * 2019-12-31 2020-05-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN111150842A (zh) * 2019-12-31 2020-05-15 优锐生物医药科技(深圳)有限公司 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用
CN111333733A (zh) * 2019-04-29 2020-06-26 中国人民解放军军事科学院军事医学研究院 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用
CN119060144A (zh) * 2024-10-31 2024-12-03 南京澄实生物医药科技有限公司 一种预防犬瘟热病毒感染的融合蛋白和疫苗及其应用

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US20120015000A1 (en) * 2008-06-30 2012-01-19 David Lanar Malaria vaccine of self-assembling polypeptide nanoparticles
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
SI2759306T1 (sl) * 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
WO2010092963A1 (ja) * 2009-02-10 2010-08-19 国立大学法人 琉球大学 薬物運搬体並びにこれを利用したアジュバントおよびワクチン
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
ES2641892T3 (es) * 2009-08-26 2017-11-14 Selecta Biosciences, Inc. Composiciones que inducen la ayuda de las células T
CN102939101A (zh) * 2010-01-26 2013-02-20 科罗拉多大学董事会，法人 用于通用疫苗的流感病毒组合物和方法
CA2798739A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
CA2833425C (en) * 2011-04-07 2018-08-21 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Protease cleavage site peptides as an hiv vaccine
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
SI23902A (sl) * 2011-10-07 2013-04-30 Kemijski inštitut Samosestavljivi polipeptidni poliedri
US9550813B2 (en) 2012-05-22 2017-01-24 The Board Of Trustees Of The Leland Stanford Junior University Disulfide stabilized foldon polypeptides
CN104582714A (zh) * 2012-05-23 2015-04-29 斯坦福大学托管董事会 流感疫苗构建体
EP2703483A1 (en) * 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
JP2016532712A (ja) * 2013-09-05 2016-10-20 イミューン デザイン コーポレイション 薬物中毒に対するワクチン組成物
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
EP3250233A4 (en) * 2015-01-29 2018-07-25 Agency for Science, Technology and Research Nanocapsules carrying chikungunya-associated peptides
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US9944679B2 (en) 2015-03-16 2018-04-17 The Catholic University Of America Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
WO2016207782A1 (en) * 2015-06-22 2016-12-29 STRELNIKOV, Evgeny Immunogenic synthetic oligopeptides for a vaccine against hiv
CN105393976A (zh) * 2015-10-30 2016-03-16 河南科技学院 一种利用ghrelin促进新生雏鸡生长性能的方法及应用
CN105409831A (zh) * 2015-10-30 2016-03-23 河南科技学院 一种利用ghrelin减少新生雏鸡脂肪细胞分化和降低脂肪沉积的方法及应用
CN105210995A (zh) * 2015-10-30 2016-01-06 河南科技学院 一种利用ghrelin促进新生雏鸡免疫器官发育的方法及应用
US10188136B2 (en) 2016-02-16 2019-01-29 Indian Institute Of Science Education And Research Hydrophobin mimics: process for preparation thereof
FR3050448A1 (fr) * 2016-04-21 2017-10-27 Bioaster Nanoparticules a base d'encapsuline.
IL299962A (en) 2016-05-02 2023-03-01 Scripps Research Inst Compositions and methods related to HIV-1 immunogens
SG10201912944QA (en) 2016-09-02 2020-02-27 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2018154010A1 (en) 2017-02-23 2018-08-30 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
WO2019023811A1 (en) 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2018358238B2 (en) * 2017-11-01 2022-08-18 The Scripps Research Institute Novel scaffolded HIV-1 vaccine immunogens
JP7314441B2 (ja) * 2018-01-22 2023-07-26 国立感染症研究所長 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原
US11225502B1 (en) * 2018-06-11 2022-01-18 Battelle Memorial Institute Controlled synthesis of hierarchically-structured hybrid materials through peptoid engineering
WO2019241483A1 (en) 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
RU2713723C1 (ru) * 2018-11-15 2020-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Искусственные гены, кодирующие белки-иммуногены EV.CTL и EV.Th, рекомбинантные плазмидные ДНК pEV.CTL и pEV.Th, обеспечивающие экспрессию искусственных генов, и искусственные Т-клеточные полиэпитопные белки-иммуногены EV.CTL и EV.Th, содержащие эпитопы антигенов вируса Эбола, используемые для создания вакцины против вируса Эбола
CA3126544A1 (en) 2019-01-12 2020-07-16 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CN112022066A (zh) * 2020-09-25 2020-12-04 电子科技大学 一种基于深度学习的消化道钩虫发现方法及系统
WO2022106860A1 (en) * 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
WO2022149609A1 (ja) * 2021-01-07 2022-07-14 国立大学法人東京工業大学 Ｍｈｃ分子に適合する病原微生物由来のペプチドが担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン、並びに、免疫後の生理活性物質の分泌に関する情報の取得方法
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
CA2037151A1 (en) * 1990-03-23 1991-09-24 F. Hoffmann-La Roche Ag Plasmodium sporozoite antigen
IL109664A0 (en) * 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
CA2337754C (en) * 1998-08-21 2011-05-24 Altaf A. Lal Recombinant multivalent malarial vaccine against plasmodium falciparum
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
US6756039B1 (en) * 1999-05-10 2004-06-29 The Regents Of The University Of California Self assembling proteins
WO2001000010A1 (en) * 1999-06-25 2001-01-04 Kondejewski Leslie H Polypeptide compositions formed using a coiled-coil template and methods of use
JP2003532740A (ja) * 2000-05-05 2003-11-05 アフトン コーポレーション キメラペプチド免疫原
WO2002100325A2 (en) * 2000-10-13 2002-12-19 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
AU2002349204A1 (en) * 2001-11-26 2003-06-10 University Health Network Self-assembling p53 peptides as gene delivery vehicles
DE602004008582T2 (de) * 2003-02-17 2008-05-21 Peter Burkhard Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011065A (zh) * 2011-08-23 2014-08-27 哈佛大学校长及研究员协会 肽纳米粒子及其用途
CN104011065B (zh) * 2011-08-23 2017-06-30 哈佛大学校长及研究员协会 肽纳米粒子及其用途
CN104136454A (zh) * 2011-10-12 2014-11-05 阿尔法-O肽股份公司 作为针对诺如病毒感染的疫苗的自装配肽纳米粒
CN105960412A (zh) * 2014-01-09 2016-09-21 阿尔法欧多肽股份公司 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒
CN105960412B (zh) * 2014-01-09 2021-04-27 阿尔法欧多肽股份公司 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒
CN110290805A (zh) * 2017-01-03 2019-09-27 埃默杰克斯疫苗控股有限公司 通用流感疫苗组合物
US12605439B2 (en) 2017-01-03 2026-04-21 Gylden Pharma Limited Universal influenza vaccine compositions
CN110996995A (zh) * 2017-03-23 2020-04-10 阿尔法-O肽股份公司 具有内置六螺旋束蛋白的自组装蛋白纳米粒子
CN111333733A (zh) * 2019-04-29 2020-06-26 中国人民解放军军事科学院军事医学研究院 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用
WO2020220846A1 (zh) * 2019-04-29 2020-11-05 中国人民解放军军事科学院军事医学研究院 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用
CN111333733B (zh) * 2019-04-29 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用
CN111150842A (zh) * 2019-12-31 2020-05-15 优锐生物医药科技(深圳)有限公司 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN111150842B (zh) * 2019-12-31 2023-09-05 优锐生物医药科技(深圳)有限公司 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用
CN111150841A (zh) * 2019-12-31 2020-05-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN119060144A (zh) * 2024-10-31 2024-12-03 南京澄实生物医药科技有限公司 一种预防犬瘟热病毒感染的融合蛋白和疫苗及其应用

Also Published As

Publication number Publication date
RU2540871C2 (ru) 2015-02-10
EP2235043A2 (en) 2010-10-06
RU2010135965A (ru) 2012-03-10
US8546337B2 (en) 2013-10-01
CA2713879C (en) 2020-01-07
WO2009109428A3 (en) 2010-04-01
WO2009109428A2 (en) 2009-09-11
AU2009221419B2 (en) 2013-09-26
JP6088123B2 (ja) 2017-03-01
JP2011511773A (ja) 2011-04-14
AU2009221419A1 (en) 2009-09-11
US20110020378A1 (en) 2011-01-27
CA2713879A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
CN101932594A (zh) 可用作疫苗的自装配肽纳米颗粒
US11324836B2 (en) Modified virus-like particles of CMV
DK2547364T3 (en) Peptides, conjugates and methods for increasing the immunogenicity of a vaccine
AU2012204955B2 (en) Monomeric and multimeric immunogenic peptides
Monso et al. Influence of conjugation chemistry and B epitope orientation on the immune response of branched peptide antigens
CN101141979A (zh) 猫变应原融合蛋白及其用途
US10501499B2 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
US20140242104A1 (en) Self-assembling peptide nanoparticles as vaccines against infection with norovirus
CN101848730B (zh) 衣壳蛋白及其用途
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
EP2012829A2 (en) Method for producing viral vaccine and therapeutic peptide antigens
JP2024502823A (ja) 安定なコロナウィルスタンパク質およびそのワクチン組成物
Bárcena et al. Design of novel vaccines based on virus-like particles
HK1152533A (en) Self-assembling peptide nanoparticles useful as vaccines
US11535651B2 (en) Hepatitis B nanoparticle-based vaccine for influenza virus
CN115916237A (zh) 抗病毒病原体的疫苗
HK40077650B (zh) Cmv的修饰病毒样颗粒
Yan et al. Strategies for designing peptide immunogens to elicit α-helical conformation-specific antibodies reactive with native proteins
BR112017008266B1 (pt) Partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv) e composição farmacêutica
JP2014508144A (ja) 免疫応答を刺激するためのプラットフォーム技術を利用するコンジュゲート

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1152533

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101229

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1152533

Country of ref document: HK